Safety data on AstraZeneca anemia drug points to potential use in dialysis

AstraZeneca said on Friday that safety data on roxadustat underpinned the British drugmaker's hopes for the anemia drug to become a standard treatment for patients with kidney disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

ConclusionsDuring and following implementation of adult epo dosing guidelines, transfusion and anemia frequency increased in pediatric HD patients. Ideal target hemoglobin levels for pediatric dialysis patients warrant further study.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
This study aimed to determine the prevalence of anemia and its associated factors among CKD patients at the University of Gondar hospital, Northwest Ethiopia. Methods: A hospital-based cross-sectional study was conducted from May 1, to September 30, 2018. Consecutive sampling was used to recruit 251 study subjects. Patients were interviewed to obtain demographic data, and the patients' medical records were reviewed to obtain information on relevant medical history and laboratory parameters. Data was analyzed using SPSS version 20. Bivariate and multivariate logistic regression analyses were used to identify independent...
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
7 November 2019 -- AstraZeneca today presented detailed results from the Phase III OLYMPUS and ROCKIES trials showing that roxadustat significantly increased hemoglobin (Hb) levels in both non-dialysis-dependent (NDD) and dialysis-dependent...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
This study investigated the association between vitamin D receptor (VDR) genetic variant (FokI) rs2228570 with iron indices (serum iron, transferrin, transferrin saturation, and ferritin). Sixty adequately hemodialyzed patients subdivided into two groups; 31 patients with transferrin saturation (TSAT)  20% who received I.V sodium ferric gluconate, calcium, and vitamin D. Sixty normal healthy were selected as the control group.. VDR genetic variant (SNP rs2228570) was genotyped in all subjects using PCR/RFLP. HD patients showed a higher frequency of rs2228570 FF genotype (38.3%) than controls (31.7%). The freq...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
PMID: 31686463 [PubMed - in process]
Source: Croatian Medical Journal - Category: General Medicine Authors: Tags: Croat Med J Source Type: research
AbstractHemolytic uremic syndrome is commonly caused by Shiga toxin-producingEscherichia coli (STEC). Up to 15% of individuals with STEC-associated hemorrhagic diarrhea develop hemolytic uremic syndrome (STEC HUS). Hemolytic uremic syndrome (HUS) is a disorder comprising of thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. The kidney is the most commonly affected organ and approximately half of the affected patients require dialysis. Other organ systems can also be affected including the central nervous system and the gastrointestinal, cardiac, and musculoskeletal systems. Neurological complicat...
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research
Condition:   Anemia in Incident Dialysis Patients Interventions:   Drug: Roxadustat;   Drug: Epoetin Alfa Sponsor:   Second Xiangya Hospital of Central South University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clini...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
This article examines the recently published guidelines for ESA use in cancer patients from the American Society of Clinical Oncology and American Society of Hematology and attempts to contextualize them to the care of patients with coexistent CKD, cancer, and anemia. PMID: 31596520 [PubMed - as supplied by publisher]
Source: Seminars in Dialysis - Category: Urology & Nephrology Authors: Tags: Semin Dial Source Type: research
More News: Anemia | AstraZeneca | Dialysis | Health | UK Health | Urology & Nephrology